We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.
Last updated: 22 January 2018
Following a temporary supply constraint, Twinrix adult [720/20] [combined hepatitis A and hepatitis B vaccine], Twinrix Junior (combined hepatitis A and hepatitis B vaccine) and Engerix-B paediatric [hepatitis B surface antigen recombinant (yeast) vaccine] are now back in stock in Australia.
Engerix-B adult (hepatitis B surface antigen recombinant (yeast) vaccine)
This vaccine is experiencing a long-term supply constraint in Australia due to a disruption in the manufacturing process. Production is now back to normal, however it will take time to re-build capacity. We expect to provide the next update on supply of this vaccine later in 2018.
GSK prioritises hepatitis B vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Engerix-B to all Australian State, Territory and Federal Government vaccination programs where Engerix-B is the vaccine of choice.
We understand that this stock-out may be distressing for those who are not covered by government programs and who may be required to vaccinate themselves for occupational reasons or because they are planning on travelling to hepatitis-affected areas.
Please visit the TGA website for ongoing updates to supply.
For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.